Over the past few weeks, the peptide industry has experienced two developments that, on the surface, appear unrelated. First, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced that the federal government is considering loosening restrictions on a group of peptides previously restricted by the FDA. Second, one of the most recognizable suppliers in the research peptide market — Peptide Sciences — announced that it was voluntarily shutting down operations. Individually, each event is significant. Taken together, the timing raises an interesting question: Could these two developments actually be connected? 🧪 RFK Jr.’s Announcement About Previously Restricted Peptides During a recent appearance on the Joe Rogan Experience, Kennedy discussed the FDA’s earlier crackdown on peptide compounding and signaled that the agency may soon reverse course on several of those restrictions. The FDA had previously placed 19 peptides on its Category 2 bulk drug substances list, a classification that effectively prevented traditional compounding pharmacies from preparing them. Kennedy indicated that the agency is now reviewing that decision and that roughly 14 of those peptides could be moved back into a category that allows compounding pharmacies to produce them under physician supervision. Among the peptides widely discussed as part of this shift are compounds frequently referenced in longevity and recovery research circles, including: • BPC-157 • Thymosin Alpha-1 • TB-500 (Thymosin Beta-4 fragment) • AOD-9604 • GHK-Cu • several growth hormone related peptides These compounds were originally restricted by the FDA in 2023 due to concerns about insufficient human safety data and the lack of formal drug approval pathways. Kennedy’s argument is that removing them from legal compounding pushed demand toward unregulated gray-market suppliers rather than improving patient safety. ⚗️ The Gray Market That Emerged When compounding pharmacies lost the ability to produce these peptides, demand did not disappear.

Hi everyone — quick note as we get settled here. We’re intentional about the groups we join. We try to participate only in communities where we feel we can add value, offer a parallel industry perspective, and contribute insights that are genuinely useful to the discussion — not distract from it. Our goal isn’t to poach members, redirect traffic, or conflict with the culture of any group. We aim to share perspectives, research, and discussion points that complement what’s already happening here. That said, we fully understand we won’t be for everyone. If any post, comment, or topic ever feels off-tone or misaligned, we’re very open to feedback. A quick DM or note is always welcome, and we’re happy to adjust how we engage within the group. Appreciate the space, and looking forward to contributing where it makes sense. (Part 1 of our TPDB series: Risk — The Numbers They Don’t Want You to Understand) If you’ve ever read a headline that made you feel a sudden jolt of fear — “risk doubles,” “danger spikes,” “linked to cancer,” “raises mortality” — there’s a good chance you were reacting not to facts, but to a statistical illusion most people don’t realize they’ve fallen for. Almost nobody is taught how to read risk properly. And that’s exactly why this trick works so well. 🧮 Two Different Numbers — Two Very Different Realities You’ll never understand health statistics (or media manipulation) until you understand these two terms: 1. Absolute Risk This is the actual, real-world probability that something will happen. Example: “3 out of 1,000 people will experience this in the next 10 years.” Absolute risk tells you the size of the danger in real life. 2. Relative Risk This is a comparison — how much higher or lower a risk is in one group compared to another. Example: “People who do X have twice the risk of Y.” Relative risk tells you how groups differ, but it hides the actual numbers beneath the comparison. 🔥 Where the Manipulation Happens If your absolute risk goes from 2 in 1,000 → 3 in 1,000, that is a tiny absolute change…

Hey everyone — we’re running a short anonymous community survey, and your input would seriously help shape what we build next. This is not a marketing funnel. This is not a lead capture. And you will never be marketed to because of it. This survey exists for one reason: 👉 To understand the real challenges people are facing with peptides, supplements, sourcing, tracking, biohacking, protocols, confusion, and mixed information… …so we can build smarter tools, guides, and resources that actually solve those problems. If you want a copy of the final aggregated data, you can request it at the end, free. No catch. It only takes about 3–4 minutes, and your input genuinely moves the entire community forward. 🔗 Take the survey here: The Future of Supplement & Peptide Tracking Thank you in advance — the more people who contribute, the clearer the signal we get. Let’s make this next year the one where confusion drops and clarity wins. 💥

Our good friend Alejandra Sol Garcia is joining an expert panel this evening for a big conversation on the future of peptides — and it would be amazing if we could all show up and support her. 🧬 Wednesday PEP TALK 📅 12/10 ⏰ 5:30 PM PST 🎙 Topic: The Future of Peptides — featuring an expert panel 🔐 Zoom (secured):https://us02web.zoom.us/j/83900021985 When you join, drop in the chat that you’re there to support Alejandra — let’s show her some love and represent the community strong. And, give a big shoutout to our crew over at Skool for helping to keep us connected and coordinate these opportunities to participate in the industry:👉 https://www.skool.com/the-peptide-daily-brief Please set a reminder and share this invite with a few others to help boost the crowd. Thanks, everyone! ⏰🔥